|Bid||2.9300 x 800|
|Ask||2.9600 x 800|
|Day's Range||2.9100 - 2.9940|
|52 Week Range||1.8000 - 4.8500|
|Beta (5Y Monthly)||0.90|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
By Jarrett Banks Roumell Asset Management LLC filed an amended 13D on Enzo Biochem Inc. expressing its disapproval that the company hasn’t accepted Co-Founder Elazar Rabbani’s board resignation. Enzo Biochem, Inc., founded in the 1970s, has frustrated investors with a poor operational and share-price performance over the last several years. CorpGov has covered the story extensively. “Shareholders demonstrated […]
Enzo Biochem, Inc. ( NYSE:ENZ ) shareholders should be happy to see the share price up 26% in the last quarter. But...
Enzo Biochem registered $31.5 million in sales in the latest quarter, up from $19.4 million last year, and earnings swung to a gain from a loss.